Literature DB >> 531409

[Amiodaron neuropathy: clinical and pathological study of a new drug induced lipidosis (author's transl)].

P Dudognon, J J Hauw, C de Baecque, J P Derrida, R Escourolle, E J Nick.   

Abstract

The authors report a case of amiodaron-induced neuropathy in a seventy one years old man. First signs appeared seventeen months after the treatment was started with 400 mg/day for one year and continued with 200 mg/day. Examination on the 29th month disclosed a severe sensory and motor deficit of the limbs with distal predominancy. Motor nerve conduction velocity was strongly impaired without modification of distal latencies. Fundi were normal. The patient improved quickly after drug withdrawal. The authors review the rare similar cases reported in the literature and attempt to describe the clinical caracteristics of amiodaron neuropathy. Qualitative and quantitative light and electron microscopical studies of nerve, muscle and skin biopsies, including teased fibers preparations were performed and they disclosed a marked reduction of the number of myelinated fibers. Wallerian degeneration predominated (31 p. 100) other segmental demyalination (25 p. 100). Numerous polymorphous lipid-laden lysosomes were present in Schwann cells, fibrocytes, pericytes, endothelial and muscle cells. These previously undescribed morphological findings are similar to those present in perhexiline maleate intoxications. We believe amiodaron neuropathy is a new neuropathy with drug-induced lipidosis.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 531409

Source DB:  PubMed          Journal:  Rev Neurol (Paris)        ISSN: 0035-3787            Impact factor:   2.607


  9 in total

1.  'White elephants' and a distinguished monkey - or the need for a proactive follow-up in amiodarone therapy.

Authors:  Chr van Tellingen
Journal:  Neth Heart J       Date:  2004-10       Impact factor: 2.380

2.  Can amiodarone induce hyperglycaemia and hypertriglyceridaemia?

Authors:  A Politi; G Poggio; A Margiotta
Journal:  Br Med J (Clin Res Ed)       Date:  1984-01-28

Review 3.  Amiodarone: the experience of the past decade.

Authors:  W J McKenna; E Rowland; D M Krikler
Journal:  Br Med J (Clin Res Ed)       Date:  1983-12-03

4.  Familial disorder of the central and peripheral nervous systems with particular cytoplasmic lamellated inclusions in peripheral nerves, muscle satellite cells, and blood capillaries.

Authors:  F M Tomé; P Brunet; M Fardeau; F Hentati; J Reix
Journal:  Acta Neuropathol       Date:  1985       Impact factor: 17.088

5.  Peripheral neuropathy during longterm high-dose amiodarone therapy.

Authors:  A G Fraser; I N McQueen; A H Watt; M R Stephens
Journal:  J Neurol Neurosurg Psychiatry       Date:  1985-06       Impact factor: 10.154

6.  Antiarrhythmic drugs and polyneuropathy. The Collaborative Group for the Study of Polyneuropathy.

Authors: 
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-03       Impact factor: 10.154

Review 7.  Experimentally induced lipidosis in rat retinal pigment epithelium. A brief review.

Authors:  R Lüllmann-Rauch
Journal:  Albrecht Von Graefes Arch Klin Exp Ophthalmol       Date:  1981

8.  The induction of pulmonary phospholipidosis and the inhibition of lysosomal phospholipases by amiodarone.

Authors:  M F Heath; F R Costa-Jussà; J M Jacobs; W Jacobson
Journal:  Br J Exp Pathol       Date:  1985-08

9.  Amiodarone-induced hepatitis and polyneuropathy.

Authors:  Hyun Mo Kang; Yoon Sae Kang; Seok Hyun Kim; Jae Kyu Seong; Dae Young Kang; Heon Young Lee; Byung Seok Lee
Journal:  Korean J Intern Med       Date:  2007-09       Impact factor: 2.884

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.